As previously announced, Advarra, Inc. (“Advarra”) acquired Quorum Review, Inc. (“Quorum”) effective February 28, 2019.
On May 1, 2019, all new studies submitted will be managed under Advarra’s FDA/OHRP registration (IRB00000971). Advarra (IORG000635) will begin transferring all ongoing studies previously under Quorum IRB oversight to Advarra IRB, and all studies will fall under the Advarra FDA/OHRP registration once the transfer is complete. Quorum’s FDA/OHRP registration (IRB00003226) will remain active in the interim under the Advarra name. Once all Quorum studies are transferred, the Quorum registration number will be deactivated.
The FDA does not require that an updated or new 1572 be completed to reflect this change in information; however, FDA recommends that the investigator document the change in the clinical study records and inform the sponsor of these changes.1 This Note to File may serve as this documentation. Click here to access a downloadable PDF version of this information.
The following addresses should be used for new 1572s:
|Studies reviewed by the US board||Advarra
6940 Columbia Gateway Drive, Suite 110
Columbia, Maryland 21046
|Studies reviewed by the Canadian board||Advarra
300-372 Hollandview Trail
Aurora, ON L4G 0A5
We look forward to continuing our relationship with your company.
Chief Compliance Officer and Institutional Official, Advarra
1Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs, Frequently Asked Questions – Statement of Investigator (Form FDA 1572), May 2010, available at https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM214282.pdf